Trebananib
Trebananib (2xCon4C) is an Fc fusion peptibody. Trebananib exerts its effects by blocking the binding of angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) to the TIE2 receptor. Trebananib has anti-angiogenic and anti-tumor activities[1][2][3].
Product Specifications
CAS Number
894356-79-7
Product Name Alternative
2xCon4C; AMG 386
UNSPSC
12352203
Target
Tie
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/trebananib.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Trebananib]
Molecular Weight
(63.25 kDa)
References & Citations
[1]Moore KN, et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol. 2015 Sep;138 (3) :513-8.|[2]Herbst RS, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009 Jul 20;27 (21) :3557-65.|[3]Elbanna M, et al. Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Mol Cancer Ther. 2020 Jan;19 (1) :147-156.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470371-500 1x 500 µL
Cytokeratin, pan (AE-1 / AE-3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
KN400508 1 Kit
ATP citrate lyase (ACLY) Human Gene Knockout Kit (CRISPR)
Sign In for Pricing
View Details 